Introduction: Clinical Context and Unmet Need in X-Linked Retinitis Pigmentosa
X-linked retinitis pigmentosa (XLRP) is a severe inherited retinal dystrophy characterized by progressive photoreceptor degeneration leading to night blindness, peripheral vision loss, and eventual blindness. Mutations in the RPGR gene, particularly in the ORF15 isoform, account for the majority of XLRP cases. The RPGR ORF15 region, however, is notoriously difficult to clone and express due to its repetitive, unstable sequence prone to secondary structures and cryptic splicing, which historically has posed significant challenges to gene replacement therapy development. Existing treatment strategies remain largely supportive, underscoring the critical unmet need for effective molecular therapies that halt or reverse photoreceptor degeneration in XLRP patients.
Study Design and Methodology
This study presents a prospective experimental approach utilizing an optimized RPGR ORF15 transgene delivered via recombinant adeno-associated virus serotype 5 (rAAV5) to overcome inherent cloning instability and enhance therapeutic efficacy. The investigators engineered a codon-optimized RPGR sequence designed to eliminate problematic secondary structures and cryptic splice sites, validated expression in HEK 293T and photoreceptor-like 661W cells in vitro, and created a robust Rpgr knockout (Rpgr-KO) mouse model exhibiting severe photoreceptor loss and functional deficits.
Subretinal injections of rAAV5 carrying the optimized RPGR construct were administered at three escalating doses (1×10^9, 3×10^9, and 1×10^10 vector genomes per eye). Structural and functional retinal assessments, including outer nuclear layer thickness and electroretinography (ERG) parameters, were performed at extended time points of 12 and 14 months post-injection to evaluate long-term therapeutic impact. Safety evaluation was conducted in a rabbit model with 1-month follow-up after subretinal vector delivery.
Key Findings: Efficacy and Safety Outcomes
The optimized rAAV5-RPGR vector demonstrated a 3.3-fold increased RPGR protein expression in vitro relative to the wild-type sequence, with elimination of truncated isoforms that could potentially cause deleterious effects. Dose-dependent retinal transgene expression localized appropriately to photoreceptor inner segments, critical for physiological RPGR function.
In the severe Rpgr-KO mouse model, high-dose gene therapy (1×10^10 vg/eye) significantly preserved photoreceptor structure, as evidenced by a 42% thicker outer nuclear layer at the injection site compared to controls at 14 months (P<0.01) and significant preservation in the central retina area (P<0.05). Moreover, treatment reduced aberrant rhodopsin mislocalization, a hallmark of retinal degeneration in RPGR deficiency, signifying restored photoreceptor protein trafficking (P<0.01). Functional ERG analysis corroborated structural findings, with treated animals exhibiting significantly improved scotopic a-wave amplitudes reaching ≥100 μV compared to <90 μV in untreated controls, and photopic b-wave amplitudes improved from 31-46 μV to 49-66 μV at standardized stimulus intensities.
Importantly, no vector-related toxicity or adverse effects were observed in the rabbit safety model, suggesting a favorable safety profile for this gene therapy approach.
Expert Commentary and Mechanistic Insights
These results offer compelling preclinical proof-of-concept for using a rationally optimized RPGR ORF15 transgene delivered via rAAV5 as a gene replacement therapy for XLRP. The strategy elegantly addresses prior technical barriers related to ORF15 instability that have impeded clinical development. The targeted transgene localization to photoreceptor inner segments aligns with RPGR’s physiological role in ciliary transport and protein trafficking, which is crucial for photoreceptor maintenance and function.
While these findings are promising, translation into human clinical trials requires consideration of interspecies differences, dosing, and long-term safety. Moreover, the durability of gene expression and functional rescue in aged subjects and advanced disease states remain to be established. Nonetheless, given the currently limited therapeutic options for RPGR-associated XLRP, these preclinical advances mark a significant milestone in retinal gene therapy development.
Conclusion and Future Directions
This study successfully demonstrates that an optimized codon-engineered RPGR ORF15 delivered via rAAV5 vector can restore photoreceptor structure and partial function in a severe XLRP mouse model without detectable toxicity. This optimized vector overcomes key molecular challenges associated with the unstable wild-type ORF15 sequence and establishes a foundation for ongoing translational research and clinical evaluation. Future studies should focus on scaling safety assessments, evaluating efficacy in additional models, and initiating clinical trials to determine therapeutic potential in patients with XLRP.
Funding and Clinical Trial Registration
Details regarding funding sources and clinical trial registration numbers were not reported in the source publication.
References
Chen X, Xu X, Cao S, Pan C, Wei S, Hou B, Zhou H. Optimized AAV5-RPGR ORF15 Gene Therapy Rescues Photoreceptor Structure and Function in XLRP Mouse Model. American Journal of Ophthalmology. 2026 Jun 9. PMID: 42263801.
